Previous 10 | Next 10 |
Ublituximab used to be TGTX's second asset and a very large potential icing on the cake for the company. After umbralisib went down, ubli has become its lifeline. While data is consistently good, one wonders what the FDA asked for with the new data that led to a delay. F...
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...
Microsatellite stable colorectal cancer patients who had a molecular response who took GRANITE combination exceeded mOS of 18 months and mOS has not yet been reached. The global market opportunity for colorectal cancer is expected to reach $18.5 billion by 2023. Results from the p...
Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom. PDUFA date for potential FDA approval of Yselty for...
BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame. However, convincing proof of concept is another year away. Bicycle Therapeutics plc ( BCYC ) is co-founded by Nobel Prize winning molecular biologist Dr. Greg Winter, who is...
Rocket is running a number of successful rare disease programs. Their data so far is excellent. They have a decent cash runway. Rocket Pharmaceuticals, Inc. ( RCKT ) aims to cure rare diseases using gene therapy. Its pipeline looks like this: PIPELINE ...
OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line. Here, they have abysmally failed to make any money. Oyster Point Pharma, Inc. (OYST) has an approved p...
Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027. Interim results from the phase 2 MOMENTUM st...
Vertex Pharma develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The company has obtained approval for several products that treat forms of cystic fibrosis ("CF"). The firm’s drug pipeline includes treatments for sickle cell dise...
On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid. Vozxogo remains the main driver of revenue growth this year. If approved in Europe, the start...
News, Short Squeeze, Breakout and More Instantly...
ProShares UltraShort Nasdaq Biotechnology Company Name:
BIS Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...